FDA expedites review of Sanofi-Regeneron colon cancer drug

04/5/2012 | InPharm.com · Reuters

The FDA granted priority-review designation for Sanofi and Regeneron's colorectal cancer drug Zaltrap, or aflibercept. The partners said the drug failed to meet the main endpoint of extending overall survival in patients with metastatic androgen-independent prostate cancer in a late-stage trial.

View Full Article in:

InPharm.com · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR